Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
No formal medicinal product interaction studies have been performed with Caelyx pegylated
liposomal, although phase II combination trials with conventional chemotherapy agents have been
conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of
medicinal products known to interact with standard doxorubicin hydrochloride. Caelyx pegylated
liposomal, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other
anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian
cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were
noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and
enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin
hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially
myelotoxic agents, at the same time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
No formal medicinal product interaction studies have been performed with doxorubicin pegylated
liposomal, although phase II combination trials with conventional chemotherapy agents have been
conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of
medicinal products known to interact with standard doxorubicin hydrochloride. Doxorubicin pegylated
liposomal, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other
anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian
cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were
noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and
enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin
hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially
myelotoxic agents, at the same time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-04-16T15:10:00Z · SHA-256 749f25cb02ef3c2557fff9c44c8608815445daccd9aad038fce4e840c7fa1845 · Passage 0b9d37625b16db4ecf52c2fb81330158395a656841966e8e2e651e80dc4f39ee · Zeichen 0–1019 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.